Related Experiment Video
Updated: Aug 11, 2026
07:51
The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Published on: June 1, 2019
Should all melanoma patients undergo sentinel lymph node biopsy?
Jin Hee Ra1, Kelly M McMasters, Francis R Spitz
1Department of Surgery, Hospital of the University of Pennsylvania, PA 19104, USA.
Current Opinion in Oncology
|February 8, 2006
Summary
Sentinel lymph node biopsy aids melanoma prognosis. Further research is needed to refine patient selection for this procedure, especially for thin, thick, or recurrent melanomas.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Sentinel lymph node biopsy (SLNB) is crucial for melanoma prognosis.
- Patient selection for SLNB remains debated, particularly for thin (<1 mm), thick (>4 mm), or recurrent melanomas.
Purpose of the Study:
- To review recent findings on SLNB in melanoma patient selection.
- To identify factors predicting regional nodal metastasis and survival.
- To evaluate risk stratification models for identifying high-risk patients.
Main Methods:
- Review of studies published in the last two years.
- Analysis of factors predicting nodal metastasis and survival.
- Evaluation of risk stratification models for patient selection.
Main Results:
- Recent research focuses on identifying predictors of nodal metastasis and survival.
- Improved risk stratification models aim to better select patients for SLNB.
- Ongoing research seeks to refine indications for SLNB in specific melanoma subtypes.
Conclusions:
- Despite extensive research, definitive indications for SLNB in thin, thick, and locally recurrent melanomas require further study.
- Continued investigation is necessary to optimize SLNB patient selection and improve melanoma management.
